Copyright
©The Author(s) 2020.
World J Gastroenterol. Nov 7, 2020; 26(41): 6455-6474
Published online Nov 7, 2020. doi: 10.3748/wjg.v26.i41.6455
Published online Nov 7, 2020. doi: 10.3748/wjg.v26.i41.6455
Table 6 The summary of the main model variables in the decision analytic model assessing the cost-effectiveness of infliximab maintenance therapy relative to conventional maintenance therapy for moderate to severe Crohn’s disease in China
Model variable | Base line value | 95%CI | |
Lower limit | Upper limits | ||
Treatment efficacies of induction therapy | |||
Disease remission rate of steroids (reference) | 0.347 | 0.247 | 0.447 |
Disease remission rate ratio for infliximab relative to reference | 1.476 | 0.620 | 2.090 |
Disease remission rate ratio for infliximab plus immunosuppressant relative to reference | 2.331 | 1.639 | 3.315 |
Disease remission rate ratio for infliximab plus enteral nutrition relative to reference | 1.743 | 1.523 | 2.986 |
Treatment efficacies of maintenance therapy | |||
Quarterly risk of disease relapse associated with no treatment | 0.207 | 0.146 | 0.284 |
Relative risk of disease relapse associated with infliximab relative to no treatment | 0.040 | 0.000 | 0.140 |
Relative risk of disease relapse associated with immunosuppressant relative to no treatment | 0.360 | 0.170 | 0.630 |
Mortality | |||
Perioperative mortality rate associated with surgery | 0.014 | 0.007 | 0.030 |
Hazard ratio of mortality associated with active disease relative to age and gender-matched general population | 3.047 | 2.195 | 4.230 |
Utility ratio between CD patients and general population | |||
Disease remission | 0.829 | 0.622 | 0.994 |
Active disease | 0.743 | 0.565 | 0.926 |
Direct medical costs | |||
Annual medical costs related to disease reemission management | ¥9512 | ||
Annual medical costs related to active disease management | ¥14436 | ||
Surgery costs per episode | ¥16781 | ||
Annual drug acquisition costs of infliximab used as induction therapy | ¥49000 | ||
Drug acquisition costs of infliximab used as MT in the first year | ¥39200 | ||
Drug acquisition costs of infliximab used as MT beyond the first year | ¥29400 |
- Citation: Shi JH, Luo L, Chen XL, Pan YP, Zhang Z, Fang H, Chen Y, Chen WD, Cao Q. Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn’s disease in China. World J Gastroenterol 2020; 26(41): 6455-6474
- URL: https://www.wjgnet.com/1007-9327/full/v26/i41/6455.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i41.6455